Abstract:As a tumor suppressor, p53 protein regulates the cell cycle and is involved in preventing tumorgenesis. The protein level of p53 is under the tight control of its negative regulator human double minute 2 (HDM(2)) via ubiquitination. Therefore, the design of inhibitors of HDM(2) has attracted much interest of research on developing novel anticancer drugs. Presently, two classes of molecules, i.e., the 1,4-benzodiazepine-2,5-diones (BDPs) and N-Acylpolyamine (NAPA) derivatives were studied by three-dimensional quantitative structure-activity relationship (3D-QSAR) modeling approaches including the comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) as promising p53-HDM(2) inhibitors. Based on both the ligand-based and receptor-guided (docking) alignments, two optimal 3D-QSAR models were obtained with good predictive power of q(2) = 0.41, r(2)(pred) = 0.60 for BDPs, and q(2) = 0.414, r(2)(pred) = 0.69 for NAPA analogs, respectively. By analysis of the model and its related contour maps, it is revealed that the electrostatic interactions contributed much larger to the compound binding affinity than the steric effects. And the contour maps intuitively suggested where to modify the molecular structures in order to improve the binding affinity. In addition, molecular dynamics simulation (MD) study was also carried out on the dataset with purpose of exploring the detailed binding modes of ligand in the HDM(2) binding pocket. Based on the CoMFA contour maps and MD-based docking analyses, some key structural aspects responsible for inhibitory activity of these two classes of compounds were concluded as follows: For BDPs, the R(1) and R(3) regions should have small electronegativity groups; substituents R(2) and R(4) should be larger, and R(3) substituent mainly involves in H-bonds forming. For NAPA derivatives, bulky and electropositive groups in ring B and ring A, small substituent at region P is favorable for the inhibitory activity. The models and related information, we hope, may provide important insight into the inhibitor-p53-HDM(2) interactions and be helpful for facilitating the design of novel potent inhibitors.

Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives As P38 MAP Kinase Inhibitors by Computational Explorations

Docking and 3D-QSAR study on p38α MAP kinase inhibitors

3d-Qsar And Molecular Docking Studies On Fused Pyrazoles As P38 Alpha Mitogen-Activated Protein Kinase Inhibitors

Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives As TNF-α Release Inhibitors by in Silico Explorations

Ligand-based 3D pharmacophore design, virtual screening and molecular docking for novel p38 MAPK inhibitors

Design, Synthesis, in vitro Anti‐inflammatory Activity and in silico Studies of Imidazole‐Based 1,2,3‐Triazole Hybrids Targeting p38 MAP Kinase

Evaluation of the Combination Mode and Features of P38 MAPK Inhibitors: Construction of Different Pharmacophore Models and Molecular Docking

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Insight into the Structural Requirements of Benzimidazole Derivatives As Interleukin‐2 Inducible T‐cell Kinase Inhibitors by Computational Explorations

Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity

Structural Determinants of Benzodiazepinedione/peptide-Based P53-Hdm2 Inhibitors Using 3D-QSAR, Docking and Molecular Dynamics.

Structure-based virtual screening for novel p38 MAPK inhibitors and a biological evaluation

Structural Study of Selectivity Mechanisms for JNK3 and p38α with Indazole Scaffold Probing Compounds

Synthesis and biological assessment of triazolo-quinazoline carbothioamide derivatives for p38 MAP kinase inhibition: in-silico and in-vitro approaches

Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with P38α MAP Kinase.

Design, Synthesis, and Anti-Inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine P38alpha Mitogen-Activated Protein Kinase Inhibitors.

Binding Mechanism of Inhibitors to P38α MAP Kinase Deciphered by Using Multiple Replica Gaussian Accelerated Molecular Dynamics and Calculations of Binding Free Energies.

Design, synthesis, biological evaluation, and in silico studies of quinoxaline derivatives as potent p38α MAPK inhibitors

3D-QSAR, Molecular Docking and Molecular Dynamics Simulations Study of 3-Pyrimidin-4-yl-oxazolidin-2-one Derivatives to Explore the Structure Requirements of Mutant IDH1 Inhibitors

Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38α inhibitors

Benzothiazole Based Inhibitors of P38α MAP Kinase